AstraZeneca, MD Anderson Enter Collaboration to Help Improve Patient Outcomes in Ovarian/ Gynecologic Cancers

WILMINGTON, Del. & HOUSTON, Jan 29, 2015 -- AstraZeneca and The University of Texas MD Anderson Cancer Center today announced a multi-year, strategic research collaboration to conduct multiple, parallel clinical and clinically-related studies in ovarian and other gynecologic cancers with the aim of improving patient outcomes.

The agreement represents a unique approach to research by focusing not just on clinical trials using investigational therapies to gain profound insights and information, but also epidemiological and outcomes studies. Through this approach, AstraZeneca and MD Anderson aim to re-think how industry and academia can collaborate in deeper and broader ways to help expedite the development of treatments for women with high unmet medical needs.

The data collected from these studies is anticipated to inform the development and utility of existing and future therapies. MD Anderson scientists will have access to AstraZeneca therapeutic agents and developmental compounds, and studies will be determined by the collaboration at a later date.

"AstraZeneca is committed to helping redefine the cancer treatment paradigm, beginning with our powerful clinical development program for ovarian cancer," said Greg Keenan, Chief Medical Officer U.S., AstraZeneca. "Working to fully realize the potential of novel targeted therapies and immunotherapies, as well as novel combinations to drive improved outcomes, engages us in true partnerships to better understand the science. The collaboration with MD Anderson is ideal as it maximizes both our ability to explore these combinations through AstraZeneca's agents while providing us with unique insights and data."

The collaboration will draw on the expertise of MD Anderson's Moon Shots Program, which aims to accelerate the conversion of scientific discoveries into clinical advances and significantly reduce cancer deaths. The effort also leverages resources such as MD Anderson's Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy (IPCT) and novel agents from AstraZeneca.

"Ovarian and other gynaecologic cancers remain areas of high unmet need," said Gordon Mills, M.D., Ph.D., chair of Systems Biology, Division of Cancer Medicine at MD Anderson. Mills is co-leader of MD Anderson's Breast and Ovarian Cancer Moon Shot and co-director of the IPCT.

"Collaborations that examine new agents and explore disease epidemiology and outcomes have the potential to inform the development of novel and combination treatments, and MD Anderson has the ability and expertise required to provide data-rich, rapid trials to inform this combination strategy," said Mills.

Oncology is a core growth platform for AstraZeneca, and the company is aiming to bring six new cancer medicines to patients by 2020. AstraZeneca's broad pipeline of oncology investigational drugs is focused on four main disease areas - breast, ovarian, lung and haematological cancers. These are being targeted through four key platforms - immunotherapy, the genetic drivers of cancer and resistance, DNA damage repair and antibody drug conjugates (ADCs).


About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit

About MD Anderson

The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. MD Anderson is one of only 41 comprehensive cancer centers designated by the National Cancer Institute (NCI). For the past 25 years, MD Anderson has ranked as one of the nation's top two cancer centers in U.S. News & World Report's annual "Best Hospitals" survey. MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).


SOURCE: AstraZeneca and The University of Texas MD Anderson Cancer Center

Michele Meixell, +1 302-885-2677 
Alisha Martin, +1 302-885-2677 
MD Anderson 
Ron Gilmore, 713-745-1898 (Houston) 
[email protected]

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

While the biotech IPO market booms, it can look like going public is easy. But the right strategy, syndicate and aftermarket are still important.

Gene therapy pioneer Jim Wilson and the University of Pennsylvania are teaming up with Regeneron to help deliver its COVID antibody intransally.

Forty percent of PK deficiency patients on mitapivat had hemoglobalin responses, compared to 0% in the placebo group.